Erektilní dysfunkce a její lécba – farmakologický a klinický profil avanafilu
| Title in English | ERECTILE DYSFUNCTION AND ITS TREATMENT – PHARMACOLOGICAL AND CLINICAL PROFILE OF AVANAFIL |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Urologické listy |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | erectile dysfunction; treatmen;t phosphodiesterase 5 inhibitors; avanafil |
| Description | Modern ED therapy, which in the first line consists of PDE5 inhibitors (PDE5-I) application, is safe and effective and is well tolerated. Avanafil, a new agents, is a highly potent PDE5 inhibitor and highly selective for PDE5. Results of phase III clinical trials suggest that avanafil is an effective and well tolerated treatment for ED of broad-spectrum aetiology and severity. The improvement in sexual function and tolerability coupled with the rapid onset of action and durability of effect make avanafil a viable tool for on demand treatment of ED. |